Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 26, 2025 08:30 ET | Source: Celularity Inc.

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases,...
December 22, 2025 16:01 ET | Source: Celularity Inc.

Celularity Announces Closing of Financing Transactions

FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases,...
December 18, 2025 14:10 ET | Source: Celularity Inc.

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

The contemplated financing transactions would provide up to $12 Million in capital to support Celularity’s strategic priorities around longevity and preservation of human performance. FLORHAM PARK,...
October 30, 2025 08:00 ET | Source: Celularity Inc.

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

Celularity has entered into a strategic partnership with DefEYE, granting DefEYE an exclusive sublicense for Celularity’s ophthalmic biologics portfolio
October 14, 2025 08:45 ET | Source: Celularity Inc.

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery diseaseCelularity PDA-002 achieved durable wound healing with just two intramuscular dosesAs a qualified...
June 02, 2025 08:00 ET | Source: Celularity Inc.

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstructionSupports broad range of regenerative...
May 30, 2025 17:30 ET | Source: Celularity Inc.

Celularity Receives Nasdaq Notice Regarding Form 10-Q

FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that on May 28,...
May 09, 2025 09:15 ET | Source: Celularity Inc.

Celularity Announces Full Year 2024 Operating and Financial Results

FLORHAM PARK, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced operating and...
April 25, 2025 17:30 ET | Source: Celularity Inc.

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has...
April 14, 2025 08:00 ET | Source: Celularity Inc.

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

FLORHAM PARK, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, welcomes action by the Centers...